Successful treatment of refractory disseminated Mycobacterium avium complex infection with the addition of linezolid and mefloquine.
Execpt in patients with AIDS, disseminated MAC infection has been rare. We describe a patient with chronic lymphatic leukemia who developed disseminated cutaneous MAC lesions refractory to conventional antimycrobial therapy. The lesions responded to the addition of compounds that were recently discovered to have anti-MAC activity (linezolid, moxifloxacin) as well as GM-CSF.
Nannini
Esteban C
EC
Department of Infectious Diseases, The University of Texas, M. D. Anderson Cancer Center, Houston, TX 77030, USA.
Keating
Michael
M
Binstock
Peter
P
Samonis
George
G
Kontoyiannis
Dimitrios P
DP
D000081:Acetamides / Q000627:therapeutic use*; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D001372:Aza Compounds; D017291:Clarithromycin / Q000627:therapeutic use; D004359:Drug Therapy, Combination / Q000627:therapeutic use; D004977:Ethambutol / Q000627:therapeutic use; D017809:Fatal Outcome; D024841:Fluoroquinolones; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000627:therapeutic use; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000150:complications*; D000069349:Linezolid; D008297:Male; D015767:Mefloquine / Q000627:therapeutic use*; D008875:Middle Aged; D000077266:Moxifloxacin; D015269:Mycobacterium avium Complex / Q000302:isolation & purification*; D015270:Mycobacterium avium-intracellulare Infection / Q000150:complications* / Q000188:drug therapy* / Q000382:microbiology; D023303:Oxazolidinones / Q000627:therapeutic use*; D011804:Quinolines
D000081:Acetamides; D000900:Anti-Bacterial Agents; D001372:Aza Compounds; D024841:Fluoroquinolones; D023303:Oxazolidinones; D011804:Quinolines; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D004977:Ethambutol; D017291:Clarithromycin; D000069349:Linezolid; D015767:Mefloquine; D000077266:Moxifloxacin